Double financing balance
As of March 10, the two financial balances of Shanghai Stock Exchange reported 916656 billion yuan, an increase of 66 million yuan over the previous trading day; The two financial balances of Shenzhen Stock Exchange reported 795658 billion yuan, a decrease of 188 million yuan compared with the previous trading day; The two cities totaled 1712314 billion yuan, a decrease of 122 million yuan over the previous trading day.
Latest views
On Thursday, the three major A-share indexes opened sharply higher, remained high throughout the day and fell slightly in the afternoon. Individual stocks showed a general upward trend, medicine, new energy and other performance were eye-catching, and oil and precious metals fell. As of the close, the Shanghai stock index rose 1.22%, the Shenzhen Component Index rose 2.18%, the gem index rose 2.67%, the Shanghai and Shenzhen 300 rose 1.57%, the Shanghai Stock Exchange 50 rose 0.90%, and the China Stock Exchange 500 rose 1.73%. The number of gainers in the two cities was 3629, higher than the average value of 2141 last week and 1080 in the previous trading day. The number of limit trading houses was 101, higher than the average value of 70 last week and 54 on the previous trading day. The number of decliners in the two cities was 983, lower than the average of 2446 last week and 3598 in the previous trading day. The number of drop limits was 5, lower than the average value of 12 last week and 28 the previous trading day. The net outflow of northbound funds was 3.374 billion yuan, with an average net inflow of 2.040 billion yuan last week and a net outflow of 10.935 billion yuan the previous trading day. The turnover of the two cities was 1079193 billion yuan, with an average value of 967208 billion yuan last week, compared with 1162329 billion yuan the previous trading day. A shares rose in large quantities, but the main increase was completed at a high opening, showing the characteristics of rising and falling as a whole. At present, the Russian Ukrainian war is still inconclusive. Under the shadow of the crude oil crisis, it is difficult for the market to strengthen continuously. For a short cycle, investors are advised to pay attention to the fluctuation rhythm of the index, and the probability of the index will show the characteristics of "one advance and one retreat".
Topic tracking
Focus today: cro, covid-19 drugs, photovoltaic equipment
\u3000\u30001. Cro theme: on February 24, the U.S. Department of health and human services released the review report on pharmaceutical supply chain safety, which eliminated the market's concerns about CXO being put into the supply chain review. In terms of supply capacity, influence and the development of innovative drugs, China's cdmo company is still in the process of enhancing its global influence and upgrading its industrial chain. In the short term, the overall valuation of China's CXO industry is at the lowest in history, and the industrial development trend is good. In the long run, China's innovative drugs have entered the achievement stage and opened the international market. Suggestions for attention: Porton Pharma Solutions Ltd(300363) ( Porton Pharma Solutions Ltd(300363) ), Kyushu Pharmaceutical ( Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) )
\u3000\u30002. COVID-19 drug theme: the China Meheco Group Co.Ltd(600056) announcement March 9th evening, the company signed an agreement with Pfizer Inc, will be responsible for the Pfizer Inc COVID-19 virus treatment Paxlovid in the Chinese mainland market during the agreement period (2022). On February 11, 2022, in accordance with the relevant provisions of the drug administration law, the State Drug Administration (nmpa) approved the import registration of Pfizer's anti SARS cov-2 therapeutic drug nematevir tablets / ritonavir tablets combination packaging (paxlovid) with conditions. It fully shows the state's attitude and demand for oral drugs as epidemic prevention and control. As of March 10, there are 2198 locally confirmed cases in China, and the covid-19 epidemic has not been alleviated. We can continue to pay attention to the concept of covid-19 drugs. Suggested attention: Fujian Cosunter Pharmaceutical Co.Ltd(300436) ( Fujian Cosunter Pharmaceutical Co.Ltd(300436) ), Shanxi C&Y Pharmaceutical Group Co.Ltd(300254) ( Shanxi C&Y Pharmaceutical Group Co.Ltd(300254) )
\u3000\u30003. Theme of photovoltaic equipment: on March 7, Liu Hanyuan, deputy to the National People's Congress and chairman of the board of directors of Tongwei group, said in an exclusive interview that over the past decade, the cost of photovoltaic power generation has decreased by more than 90%, becoming the most economical power generation mode in the world. On March 9, Zhang Jianhua, Secretary of the Party group and director of the national energy administration, said during the interview with reporters of the two sessions that we should continue to expand the supply of clean energy, strengthen the optimal combination of traditional energy and new energy, and speed up the construction of a new energy supply and consumption system. On the one hand, accelerate the construction of large-scale photovoltaic energy and non fossil energy bases; On the other hand, pay close attention to the clean and efficient utilization of coal and increase the consumption capacity of new energy. Suggested attention: Zhejiang Sunoren Solar Technology Co.Ltd(603105) ( Zhejiang Sunoren Solar Technology Co.Ltd(603105) ), Eging Photovoltaic Technology Co.Ltd(600537) ( Eging Photovoltaic Technology Co.Ltd(600537) )
Risk tips
The epidemic has not been effectively controlled, the macro economy has unexpectedly declined, the liquidity crunch has intensified, and the industrial policies are lower than expected.
